Mi-Young Ryee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mi-Young Ryee has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Laura Willing
Children's National Hospital
2 shared publications - Lilia Mucka Andrew
Division of Psychology and Behavioral Health, Children’s National Hospital, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA
2 shared publications - Ayman Saleh
George Washington University, Children’s National Hospital, Psychiatry Department, Washington, USA
1 shared publication - Irene Zhang
Division of Psychology, Children’s National Hospital, Washington, USA
1 shared publication Kirsten Russo
Department of Behavioral Psychology, Kennedy Kreiger Institute, Baltimore, USA
1 shared publication- Nicholas Lohman
Division of Psychology, Children’s National Hospital, Washington, USA
1 shared publication
Latest Publications
- 24 September 2025
- Published by Springer Nature in Child Psychiatry & Human Development
- p. 1-8
Treatment Approaches and Growth Parameters in Pediatric ADHD: Examining Differences Across Race
Racial disparities in diagnosis and treatment of pediatric mental health conditions are well-documented. Stimulants are the cornerstone of ADHD treatment, but long-term effects on growth remain a concern. We retrospectively analyzed treatment history (e.g., duration, medication, comorbidity), growth, and demographics (e.g., socioeconomic status and race) from 197 pediatric patients with ADHD. We found Black and Hispanic patients were younger, had lower socioeconomic status, and were followed for longer than White patients. Despite similar amounts of comorbidities across racial groups, White patients received more antidepressants (p < 0.001). Stimulant users were prescribed fewer atomoxetine, antidepressant, and antipsychotic medications but had longer follow-up and more total medications. We saw a significant decrease in height Z-scores for the whole cohort, and an increase in BMI Z-scores in Hispanic patients. The findings highlight disparities in pharmacological treatment of pediatric patients with ADHD and more research is needed to understand factors contributing to potential biases to reduce inequities in care and improve patient outcomes.
- 24 September 2025
- Published by Springer Nature in Child Psychiatry & Human Development
- p. 1-8
Treatment Approaches and Growth Parameters in Pediatric ADHD: Examining Differences Across Race
Racial disparities in diagnosis and treatment of pediatric mental health conditions are well-documented. Stimulants are the cornerstone of ADHD treatment, but long-term effects on growth remain a concern. We retrospectively analyzed treatment history (e.g., duration, medication, comorbidity), growth, and demographics (e.g., socioeconomic status and race) from 197 pediatric patients with ADHD. We found Black and Hispanic patients were younger, had lower socioeconomic status, and were followed for longer than White patients. Despite similar amounts of comorbidities across racial groups, White patients received more antidepressants (p < 0.001). Stimulant users were prescribed fewer atomoxetine, antidepressant, and antipsychotic medications but had longer follow-up and more total medications. We saw a significant decrease in height Z-scores for the whole cohort, and an increase in BMI Z-scores in Hispanic patients. The findings highlight disparities in pharmacological treatment of pediatric patients with ADHD and more research is needed to understand factors contributing to potential biases to reduce inequities in care and improve patient outcomes.